241 related articles for article (PubMed ID: 11363842)
21. Studies of zidovudine in combination with didanosine and zalcitabine.
Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
[TBL] [Abstract][Full Text] [Related]
22. AZT, ddI, and ddC combinations at FDA advisory hearing. Food and Drug Administration.
James JS
AIDS Treat News; 1996 Apr; (no 244):6. PubMed ID: 11363307
[TBL] [Abstract][Full Text] [Related]
23. 3TC/AZT: just another combination.
GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362997
[TBL] [Abstract][Full Text] [Related]
24. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
Lancet; 1996 Aug; 348(9023):283-91. PubMed ID: 8709686
[TBL] [Abstract][Full Text] [Related]
25. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
Cochrane Database Syst Rev; 2000; 2000(2):CD002038. PubMed ID: 10796851
[TBL] [Abstract][Full Text] [Related]
26. Lamivudine (3TC) approved for combination use with AZT.
James JS
AIDS Treat News; 1995 Dec; (no 236):1-5. PubMed ID: 11363049
[TBL] [Abstract][Full Text] [Related]
27. Update on clinical trials of combination therapies for HIV infection.
NIAID AIDS Agenda; 1995 Sep; ():8. PubMed ID: 11362803
[TBL] [Abstract][Full Text] [Related]
28. 3TC: combination trial stopped early as clinical benefit shown.
James JS
AIDS Treat News; 1996 Aug; (no 252):5. PubMed ID: 11363752
[TBL] [Abstract][Full Text] [Related]
29. Nipping HIV in the bud.
Smart T
GMHC Treat Issues; 1996 Aug; 10(8):3-6. PubMed ID: 11363719
[TBL] [Abstract][Full Text] [Related]
30. Merck protease inhibitor: more news from Retroviruses Conference.
James JS
AIDS Treat News; 1996 Feb; (no 241):1-3. PubMed ID: 11363186
[TBL] [Abstract][Full Text] [Related]
31. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
Hammer SM; Katzenstein DA; Hughes MD; Gundacker H; Schooley RT; Haubrich RH; Henry WK; Lederman MM; Phair JP; Niu M; Hirsch MS; Merigan TC
N Engl J Med; 1996 Oct; 335(15):1081-90. PubMed ID: 8813038
[TBL] [Abstract][Full Text] [Related]
32. Therapy for human immunodeficiency virus infection -- what have we learned?
Corey L; Holmes KK
N Engl J Med; 1996 Oct; 335(15):1142-4. PubMed ID: 8813046
[No Abstract] [Full Text] [Related]
33. Back to the nukes.
Smart T
GMHC Treat Issues; 1996 Feb; 10(2):6-7. PubMed ID: 11363383
[TBL] [Abstract][Full Text] [Related]
34. Zidovudine and lamivudine: results of phase III studies.
Staszewski S
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
[TBL] [Abstract][Full Text] [Related]
35. [Anti-HIV therapy (1987-1994): from nothing to confusion].
Lissen E
Med Clin (Barc); 1995 Apr; 104(12):463-7. PubMed ID: 7739285
[No Abstract] [Full Text] [Related]
36. Making sense of 175 and Delta.
Smart T
GMHC Treat Issues; 1995 Oct; 9(10):4. PubMed ID: 11362916
[TBL] [Abstract][Full Text] [Related]
37. 3TC approved: now for the tough questions.
Mascolini M
J Int Assoc Physicians AIDS Care; 1995 Dec; 1(11):6-8. PubMed ID: 11363101
[TBL] [Abstract][Full Text] [Related]
38. AZT delta study: major European/Australian study finds combinations better than AZT alone.
King E
AIDS Treat News; 1995 Oct; (no 232):3-4. PubMed ID: 11362876
[TBL] [Abstract][Full Text] [Related]
39. 3TC and AZT.
Treat Rev; 1995; (no 17):2. PubMed ID: 11362294
[TBL] [Abstract][Full Text] [Related]
40. Antiretroviral drug resistance.
Japour AJ
AIDS Clin Care; 1995 Aug; 7(8):63-5, 67. PubMed ID: 11362787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
